Rhythm Pharmaceuticals, Inc.RYTMNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
8.79%
↓ 48% below average
Average (39q)
16.96%
Historical baseline
Range
High:329.79%
Low:-76.64%
CAGR
-5.0%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 8.79% |
| Q2 2025 | 14.43% |
| Q1 2025 | -10.19% |
| Q4 2024 | 8.53% |
| Q3 2024 | 26.37% |
| Q2 2024 | -76.64% |
| Q1 2024 | 329.79% |
| Q4 2023 | -10.96% |
| Q3 2023 | 0.08% |
| Q2 2023 | -11.60% |
| Q1 2023 | 61.14% |
| Q4 2022 | 11.52% |
| Q3 2022 | -32.87% |
| Q2 2022 | -3.24% |
| Q1 2022 | 2.96% |
| Q4 2021 | 14.65% |
| Q3 2021 | 9.70% |
| Q2 2021 | 26.08% |
| Q1 2021 | -9.31% |
| Q4 2020 | -4.53% |
| Q3 2020 | -0.01% |
| Q2 2020 | 2.19% |
| Q1 2020 | -9.29% |
| Q4 2019 | -6.63% |
| Q3 2019 | -24.74% |
| Q2 2019 | 55.12% |
| Q1 2019 | 21.31% |
| Q4 2018 | 75.27% |
| Q3 2018 | 24.71% |
| Q2 2018 | -30.13% |
| Q1 2018 | 84.67% |
| Q4 2017 | 11.42% |
| Q3 2017 | 10.64% |
| Q2 2017 | 10.75% |
| Q1 2017 | -13.46% |
| Q4 2016 | 3.91% |
| Q3 2016 | 19.52% |
| Q2 2016 | 13.07% |
| Q1 2016 | 10.83% |
| Q4 2015 | 64.60% |